Epstein Files Search

Dataset

Sort

Status

DOJ Status

Date Range

–

Page Count

–

Corpus: 1990-03-17 – 2025-12-01

April 2018

Mo

Tu

We

Th

Fr

Sa

Su

None

Light

Medium

Heavy

Results by Dataset3 total

Set 9

3

3 results for “"Phase 1/2"”

EFTA00810576Set 9

2018-04-0526p9,385w

potential in oncology — Veru is also preparing to Average 90-day Volume start a Phase

Keyboard Shortcuts

/

Focus search

Esc

Blur input

O

Open PDF

←→

Paginate

1/2

open label trial to study VERU-111, a novel, taxane-like 129,981 oral ... addition, Veru is also preparing to start a

Phase

1/2

open label trial to study VERU-111, a novel. taxane-like oral therapy for metastatic castration resistant prostate cancer (MCRPC ... very promising path ahead if it shows safety and efficacy in the

Phase

1/2

trials that are in the offing. IND submission is planned for mid-2018. We assume

https://www.justice.gov/epstein/files/DataSet%209/EFTA00810576.pdf

EFTA00810552Set 9

24p3,148w

clinical data Q1 2019 veru Successful pre-IND meeting with FDA 9/18 IND and Phase 1/2 expected calendar Q4 2018- Johns Hopkins Cancer Center (lead center) Men with metastatic castration

https://www.justice.gov/epstein/files/DataSet%209/EFTA00810552.pdf

EFTA00857649Set 9

2018-03-164p1,957w

variety of malignancies, including metastatic prostate, breast, endometrial and ovarian cancers (planned Phase 1/2 in 2018). EFTA00857650 To help support these clinical development programs, the company markets and sells

https://www.justice.gov/epstein/files/DataSet%209/EFTA00857649.pdf